On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...
Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and 25° C) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback